Investment Analysts’ Weekly Ratings Updates for Arcturus Therapeutics (ARCT)

Several brokerages have updated their recommendations and price targets on shares of Arcturus Therapeutics (NASDAQ: ARCT) in the last few weeks:

• 10/4/2026 – Arcturus Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/26/2026 – Arcturus Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/24/2026 – Arcturus Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/24/2026 – Arcturus Therapeutics had its price target lowered by BTIG Research from $23.00 to $20.00. They now have a “buy” rating on the stock.
• 9/24/2026 – Arcturus Therapeutics was upgraded by Citigroup Inc. from “neutral” to “buy”. They now have a $20.00 price target on the stock, up from $8.00.
• 9/2/2026 – Arcturus Therapeutics had its “buy” rating reaffirmed by Roth Capital. They now have a $41.00 price target on the stock.
• 8/9/2026 – Arcturus Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.